23andMe

Direct-to-consumer DNA testing services

Sunnyvale, California, United States

About 23andMe

23andMe offers direct-to-consumer DNA testing that provides individuals with insights into their ancestry, genetic traits, and potential health risks. Customers purchase a DNA testing kit, send in a saliva sample, and receive personalized genetic reports based on the analysis of their DNA. This service appeals to a wide range of people, from those curious about their family history to those wanting to understand their health predispositions. Unlike many competitors, 23andMe not only sells DNA kits but also offers subscription services for ongoing updates and insights, creating a recurring revenue model. Additionally, the company utilizes its large genetic database for research, partnering with institutions and pharmaceutical companies to advance genetic studies, which can lead to further revenue through grants and collaborations. The goal of 23andMe is to empower individuals with knowledge about their genetics while contributing to the broader field of genetic research.

Sunnyvale, CaliforniaHeadquarters
2006Year Founded
$829.6MTotal Funding
IPOCompany Stage
Biotechnology, Healthcare, Consumer GoodsIndustries
501-1,000Employees

Benefits

Comprehensive health, vision, & dental plans
Family planning, support, & leave for parents
Mental healthcare
Student loan assistance
Volunteer time off
Dog friendly office

Risks

Discontinuation of therapeutics division limits revenue diversification opportunities.
40% workforce reduction may impact operational capabilities and innovation.
Cybersecurity breach affecting 6.9 million users could damage customer trust.

Differentiation

23andMe offers direct-to-consumer DNA testing, a pioneering service in genetics.
The company provides personalized genetic reports, enhancing customer understanding of their DNA.
23andMe collaborates with research institutions, leveraging its extensive genetic database for research.

Upsides

Partnership with Nightingale Health expands service offerings beyond genetic testing.
GLP-1 telehealth service launch diversifies revenue streams in the growing telehealth market.
Biological Age feature enhances customer engagement, potentially increasing subscription uptake.

Funding

Total raised$829.64 M
Latest valuation$3.50 B
StageIPO